Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Sangeeta Raje"'
Autor:
Ellen Q. Wang, Vu Le, Jennifer A. Winton, Sakambari Tripathy, Sangeeta Raje, Lisy Wang, Martin E. Dowty, Bimal K. Malhotra
Publikováno v:
Journal of clinical pharmacology. 62(4)
Abrocitinib, an oral once-daily Janus kinase 1 selective inhibitor, is under development for the treatment of atopic dermatitis. This phase 1, nonrandomized, open-label, single-dose study (NCT03660241) investigated the effect of renal impairment on t
Autor:
Anne Hickman, Susan Zhou, Didier Saur, Steven G. Terra, David L. Cutler, Vaishali Sahasrabudhe, Kyle Matschke, Sangeeta Raje, Haihong Shi
Publikováno v:
Clinical Therapeutics. 40:1701-1710
Purpose Ertugliflozin, an oral, highly selective inhibitor of the sodium-glucose cotransporter 2, is approved in the United States and the European Union for the treatment of adults with type 2 diabetes mellitus. Hepatic impairment may affect, to var
Autor:
Klaas Schildknegt, Eric Fluhler, Lloyd Stevens, Eric Woolf, Alfin D. N. Vaz, Haihong Shi, Steven G. Terra, Dimitris Papadopoulos, Vaishali Sahasrabudhe, Didier Saur, Daniel Gaunt, Kyle Matschke, Robert J. Fountaine, Susan Zhou, David L. Cutler, Ernesto Callegari, Sangeeta Raje, Christine Alvey
Publikováno v:
Clinical and Translational Science. 11:405-411
Ertugliflozin, a sodium glucose cotransporter-2 inhibitor, is approved in the United States for treatment of type 2 diabetes mellitus. A novel two-period study design with 14 C microtracer dosing in each period was used to determine absolute oral bio
Publikováno v:
Blood. 136:33-34
Introduction: Marstacimab is a fully humanized monoclonal immunoglobulin G1 that targets the shared K2 domains of tissue factor pathway inhibitor (TFPI)α and (TFPI)β and is currently in phase 3 development. The intended indication is routine prophy
Autor:
Omoniyi J. Adedokun, Alberto Russu, Kaori Ito, Scot Styren, Chuanpu Hu, Steven Xu, Mahesh N. Samtani, H. Robert Brashear, Ming Lu, Brian Corrigan, Sangeeta Raje
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Introduction The objective of this study was to estimate longitudinal changes in disease progression (measured by Alzheimer's disease assessment scale-cognitive 11-item [ADAS-cog/11] scale) after bapineuzumab treatment and to identify covariates (dem
Publikováno v:
Translating Molecules into Medicines ISBN: 9783319500409
The development of medicines involves not only the translation of information collected in preclinical in vitro and in vivo experiments to clinical studies in healthy volunteers, also known as T1 translation, but additionally the optimization of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2ae180a48d671911c3623e01ecb3f52
https://doi.org/10.1007/978-3-319-50042-3_11
https://doi.org/10.1007/978-3-319-50042-3_11
Autor:
Sangeeta Raje, Enchi Liu, Kaori Ito, Ming Lu, Brian Corrigan, Scot Styren, Alberto Russu, Omoniyi J. Adedokun, H. Robert Brashear, Steven Xu, Chuanpu Hu, Mahesh N. Samtani
Publikováno v:
Journal of Alzheimer's disease : JAD. 53(2)
Background Bapineuzumab, an anti-amyloid monoclonal antibody, was evaluated as a candidate for immunotherapy in mild-to-moderate Alzheimer's disease (AD) patients. Objective To assess the treatment effect of bapineuzumab therapy on disease-relevant b
Autor:
Jianjing Cao, Jonathan L. Katz, Natalie D. Eddington, Sangeeta Raje, Jennifer Cornish, Amy Hauck Newman
Publikováno v:
Biopharmaceutics & Drug Disposition. 27:229-240
PURPOSE AHN 1-055, a benztropine (BZT) analog, binds with high affinity to the dopamine transporter (DAT), possesses behavioral, pharmacokinetic (PK) and brain microdialysate dopamine (DA) profiles distinct from cocaine. Accordingly, the objectives o
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 307:801-808
The N-substituted 3alpha-[bis(4'-fluorophenyl)methoxy]tropanes (AHN 2-003, AHN 1-055, AHN 2-005, and JHW 007) bind with high affinity to the dopamine transporter and inhibit dopamine uptake more potently than cocaine, but they demonstrate behavioral
Publikováno v:
Journal of Chromatography B. 768:305-313
N-Substituted 3alpha-[bis(4'-fluorophenyl)methoxy] tropanes represent a series of novel potential cocaine abuse therapeutics. AHN-1055, a member of this series, has been assessed to be the most suitable analog for pharmacokinetic studies. A sensitive